Document Detail

Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells.
MedLine Citation:
PMID:  23035972     Owner:  NLM     Status:  MEDLINE    
CONTEXT: Apoptotic neuronal cell death plays an important role in Parkinson's disease (PD), a progressive neurodegenerative disorder. Luteolin, a flavonoid, has been shown to possess various pharmacological properties including strong antioxidant capacity.
OBJECTIVE: This study investigated the neuroprotective effect of luteolin against cytotoxicity induced by 6-hydroxy-dopamine (6-OHDA) (250 µM) in rat pheochromocytoma (PC12) cell line.
MATERIALS AND METHODS: The neuroprotective effect of luteolin against 6-OHDA-induced cytotoxicity in PC12 was evaluated by using cell viability test, nuclear staining and flow cytometry. In addition, the apoptotic role of luteolin was unveiled by monitoring mRNA expression of proapoptotic and anti-apoptotic genes.
RESULTS: Pretreatment with luteolin (3.13, 6.25, 12.5, 25 or 50 µM) could markedly attenuate 6-OHDA-induced PC12 cell viability loss in a concentration-dependent manner. Cell morphologic analysis and nuclear staining assays showed that luteolin (3.13, 12.5 or 50 µM) protected the cells from 6-OHDA-induced damage. As shown in the flow cytometry assay, the increased apoptotic rate induced by 6-OHDA could be significantly (p < 0.001) suppressed by luteolin (12.5 or 50 µM) pretreatment. The protection of luteolin (50 µM) against 6-OHDA-induced cell damage was shown to be through suppressing the over-expression of Bax gene (p < 0.01), inhibiting the reduction of Bcl-2 gene expression (p < 0.05) and markedly depressing the enhanced Bax/Bcl-2 ratio. Luteolin also downregulated the gene expression level of p53.
DISCUSSION AND CONCLUSION: Luteolin has protective effects against 6-OHDA-induced cell apoptosis and might be a potential nutritional supplement which could be used to prevent neurodegenerative diseases such as PD.
De-Jian Guo; Fan Li; Peter Hoi-Fu Yu; Shun-Wan Chan
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-10-05
Journal Detail:
Title:  Pharmaceutical biology     Volume:  51     ISSN:  1744-5116     ISO Abbreviation:  Pharm Biol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-15     Completed Date:  2013-06-27     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9812552     Medline TA:  Pharm Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  190-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects*,  genetics
Cell Shape / drug effects
Cell Survival / drug effects
Dose-Response Relationship, Drug
Flow Cytometry
Luteolin / pharmacology*
Neurons / drug effects*,  metabolism,  pathology
Neuroprotective Agents / pharmacology*
Oxidopamine / toxicity*
PC12 Cells
Proto-Oncogene Proteins c-bcl-2 / genetics,  metabolism
RNA, Messenger / metabolism
Tumor Suppressor Protein p53 / genetics,  metabolism
bcl-2-Associated X Protein / genetics,  metabolism
Reg. No./Substance:
0/BAX protein, human; 0/Neuroprotective Agents; 0/Proto-Oncogene Proteins c-bcl-2; 0/RNA, Messenger; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 0/bcl-2-Associated X Protein; 8HW4YBZ748/Oxidopamine; KUX1ZNC9J2/Luteolin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identification of a rare 17p13.3 duplication including the BHLHA9 and YWHAE genes in a family with d...
Next Document:  Methyltrioxorhenium-Catalyzed Epoxidation of Homoallylic Alcohols with Hydrogen Peroxide.